CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference

October 29, 2025 5:40 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will present at the Spartan Capital Securities Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. Participation by eXoZymes underscores the conference's mission to spotlight innovative...

Read more

Imagene AI and Shaare Zedek Medical Center Form Strategic Data-AI Collaboration to Scale Oncology Research and Care

October 29, 2025 8:00 AM

Imagene AI, a pioneer in multimodal foundation models for precision oncology, and Shaare Zedek Scientific, the innovation arm of Shaare Zedek Medical Center, today announced a strategic collaboration to advance cancer research and personalized care with multimodal AI and real-world data.The collaboration brings together Shaare Zedek's real-world data, clinical research, and advanced digital infrastructure with Imagene AI's Cross-Modality...

Read more

Aspira Women's Health Wins Laboratory Service Contract with University of Texas Medical Branch at Galveston

October 29, 2025 7:00 AM

Aspira Women's Health Inc., abio-analytical-based women's health company focused on gynecologic disease diagnostics, today announced it has executed a new laboratory services agreement with University of Texas Medical Branch at Galveston ("UTMB Galveston"), a part of the University of Texas System.The initial term of the agreement is 12 months and is part of the Company's redefined marketing strategy that has prioritized marketing the Company's...

Read more

BioInvent International AB: Interim Report January - September 2025

October 29, 2025 3:20 AM

BioInvent International (STO:BINV)"The third quarter of 2025 marked continued momentum for BioInvent as we decided to focus on our most advanced programs BI-1206 and BI-1808. This strategic direction initiative is designed to accelerate the development of our most promising clinical assets and to focus on near to mid-term value creation." - Martin Welschof, CEO of BioInvent.EVENTS IN THE THIRD QUARTERStrategic changes in portfolio to accelerate...

Read more

Publication of Landmark Study in JACC: Advances

October 28, 2025 11:45 AM

GENinCode, the predictive genetics company focused on prevention of cardiovascular disease ("CVD"), announces the publication of a major clinical study in JACC: Advances evaluating its CARDIO inCode-Score Polygenic Risk Score ("PRS") for coronary heart disease ("CHD"). The study (https://share.google/nQwFO73QgGTiRqK45), was conducted at Kaiser Permanente's Departments of Research and Cardiology in Pleasanton and Oakland. CA.Study OverviewThe...

Read more

FluoGuide in Advanced Negotiations on Collaboration Agreement with a World Leading Medical Technology Company

October 28, 2025 9:00 AM

FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company specializing in precision cancer surgery, announces to be in advanced negotiations regarding a collaboration agreement with a world leading medical technology company.FluoGuide is in advanced negotiations with a world leading medical technology company on a collaboration agreement within head and neck cancer surgery where the aim is to optimize the usage of imaging...

Read more

After Five Years, VinFuture Stands as a Symbol of Confidence in Science for Humanity

October 27, 2025 11:30 AM

Professor Sir Richard Henry Friend, Chair of the VinFuture Prize Council, shared that what began as a bold idea five years ago has grown into a symbol of confidence in the power of science to serve humanity. For him, being part of VinFuture is not merely a mission, but a deeply inspiring journey-one that brings together brilliant minds from across the globe to seek out and celebrate the scientific innovations that have the power to change...

Read more

Invitation to Presentation of BioInvent's Interim Report January - September 2025

October 27, 2025 10:15 AM

BioInvent International AB ("BioInvent")(Nasdaq Stockholm:BINV)(STO:BINV) invites investors, analysts and the press to a presentation of the interim report January - September 2025 at 2:00 pm CET on Wednesday October 29. The report will be published at 8:00 am CET the same day.BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English.When: Wednesday October 29, 2025, at...

Read more

Edison Oncology Presents Two Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 27, 2025 9:00 AM

Edison Oncology, a clinical-stage biopharmaceutical company developing a pipeline of first-in-class, small-molecule, biomarker-driven therapies with potent anti-tumor activity and dedicated to accelerating cancer breakthroughs through efficient and cost-effective drug development, today announced the presentation of two abstracts at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October...

Read more

Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 2025

October 27, 2025 9:00 AM

Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30."ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by...

Read more

Cambridge Isotope Laboratories, Inc. and Chemtatva Chiral Solutions Pvt. Ltd. to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India

October 27, 2025 8:45 AM

Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of...

Read more

Lobe Sciences Completes Debt Settlement to Improve Balance Sheet

October 23, 2025 11:50 PM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies through a scalable model of shared services, global teams, and outsourced infrastructure. The Company creates intellectual property, packages it into subsidiaries, and advances each toward clinical and commercial milestones.The Company is pleased to announce closing of the settlement of USD 137,130...

Read more

CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference

October 23, 2025 4:50 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will present at the 2025 ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York City.CEO of eXoZymes, Michael Heltzen, states, "Most investors already know that - compared to the number of...

Read more

ZEO ScientifiX(TM) Positioned for New Growth as Florida Opens Stem Cell Market

October 23, 2025 8:30 AM

ZEO ScientifiX™, Inc. (OTCQB:ZEOX) ("ZEO" or the "Company"), a clinical‑stage biopharmaceutical company focused on regenerative therapies including birth tissue biologics, whole blood processing, and exosome nanoparticle science, today announced that it is prepared to capitalize on the potentially rapid expansion of Florida's regenerative medicine market following enactment of the new state stem cell law, SB 1768, effective July 1, 2025.The...

Read more

Alligator Bioscience AB Reports Financial Results for Q3 2025 and Provides a Business Update

October 23, 2025 2:25 AM

Alligator Bioscience (Nasdaq Stockholm: ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced its interim results for the third quarter of 2025 and provided a business update."This quarter represented several important steps forward for Alligator, both scientifically and strategically. The final 30-month OPTIMIZE-1 results confirm mitazalimab's unprecedented long-term...

Read more

Immortal Dragons Backs Unlimited Bio

October 22, 2025 8:15 PM

Immortal Dragons, a $40 million longevity fund, announced its strategic investment in Unlimited Bio, a biotechnology company developing combinatorial therapies to address the multi-system nature of aging.Combinatorial Therapeutic StrategyUnlimited Bio's platform integrates gene therapies, biologics, plasma-based interventions, cell therapies, and small-molecule programs targeting complementary mechanisms across organ systems. The company employs...

Read more

Notice of Extraordinary General Meeting in Alligator Bioscience AB

October 22, 2025 6:20 PM

Alligator Bioscience (STO:ATORX)The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Tuesday 25 November 2025 at 11.00 CET, at Medicon Village, conference room Bengt, Scheelevägen 4 in Lund, Sweden.RIGHT TO...

Read more

Alligator Bioscience Carries Out a Rights Issue of Units of Approximately SEK 120 Million and Raises Bridge Loans

October 22, 2025 5:20 PM

Alligator Bioscience (STO:ATORX) - The Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company") has today, subject to approval by an extraordinary general meeting on 25 November 2025, resolved to carry out an issue of ordinary shares and warrants ("units") with preferential rights for the Company's existing shareholders of initially approximately SEK 120 million (the "Rights Issue"). The Company has received...

Read more

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

October 22, 2025 9:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced that its project "AHA: Agentic Harmonization Assistant" has been selected as a semi-finalist in the prestigious $1 million Alzheimer's Insights AI Prize, Accelerating Discovery with Agentic Intelligence, a competition organized by the...

Read more

Faron Pharmaceuticals Ltd: Holding(s) in Company

October 21, 2025 9:30 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | October 21, 2025 at 16:10:00 EESTTR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd1b. Please...

Read more